Grifols revises reports of serious injuries or death at its centres down to six from 25 since 2018

Few details have been released on the incidents, however Health Canada has accepted the new numbers

theglobeandmail.com

Grifols pauses plasma collection at Canada donation centres

Private blood-plasma collector has been under scrutiny for months after the deaths of two donors

theglobeandmail.com

Health Canada backlog of generic drug applications doubled over past year

Department says growing backlog is largely due to sharp increase in submissions

theglobeandmail.com

Apotex emerges as only supplier of generic Ozempic in Canada for now

Issues at a manufacturing plant in India have sidelined two competitors

theglobeandmail.com

Health Canada says it did not consult inspector’s report in review of plasma donor’s death

Agency’s medical summary on young Winnipeg donor’s death was based on records from Grifols and Manitoba’s medical examiner

theglobeandmail.com

Trump threatens tariffs on generic drugs, complicating Canada’s on-shoring efforts

U.S. President plans to impose 100% levies on generic pharmaceuticals made abroad starting in 2028

theglobeandmail.com

No plasma was collected from Grifols donors with disease concerns flagged by Health Canada

Collector says no donor or patient was put at risk after inspection report outlined safety concerns

theglobeandmail.com

Demand for immunoglobulin treatments skyrockets in Canada

There is a push to reduce the demand for the plasma-derived therapy, as patients, physicians and governments worry about whether the growth is sustainable

theglobeandmail.com

Grifols allowed donors to give plasma despite disease concerns, Health Canada report shows

Inspectors found multiple cases of the company allowing people to donate who should have been denied because of risks associated with a fatal brain disorder

theglobeandmail.com

Auditor-General stands down in favour of government review of PrescribeIT

Audit would be duplicative of government’s efforts and offer ‘limited added value for parliamentarians and Canadians,’ the A-G said

theglobeandmail.com

Canadian Blood Services CEO defends Grifols partnership after deaths of two donors

Graham Sher says he believes the private blood-plasma collector would fix deficiencies discovered by Health Canada

theglobeandmail.com

Ottawa launches audit, review of Canada Health Infoway after $300-million PrescribeIT failure

Program was launched in 2017 as part of ‘axe the fax’ initiatives to replace fax machines with digital alternatives

theglobeandmail.com

With FDA backing, Colorado says state will save money by importing drugs from Canada

Florida was the first state to be approved for the program in 2024, but no drugs were actually shipped

theglobeandmail.com

Apotex public listing key step in renewed Canada-Americas focus, CEO says

Company began trading on the TSX last week and announced Tuesday it had completed its offering for gross proceeds of $1.495-billion

theglobeandmail.com

Ottawa puts Canada Health Infoway funding on hold after PrescribeIT failure

Health Minister Marjorie Michel says $50-million will remain withheld until the agency addresses governance concerns

theglobeandmail.com

MPs urge non-profit behind PrescribeIT to submit overdue documents to parliamentary committee

Infoway says it supplied the majority of the documents on time, but the remainder cover a ‘broad range of historical records’ that could include hundreds of thousands of pages

theglobeandmail.com

Health Canada examining concerns of family of student who died after plasma donation, minister says

Calls for more scrutiny of the circumstances surrounding the death at the for-profit donation centre came after the government’s initial report

theglobeandmail.com

Why Ottawa’s $298-million ‘axe the fax’ program PrescribeIT failed

Digital prescription program suffered from slow enrolment process, lack of national buy-in

theglobeandmail.com

Apotex expected to fetch $10-billion valuation as drugmaker files to go public on TSX

Toronto company founded by the late Barry Sherman expected to become Canada’s most valuable public life sciences company

theglobeandmail.com

Ozempic maker cuts brand-name price as generic semaglutide hits pharmacy shelves

Toronto’s Apotex prices its version of Ozempic at less than a third of the cost of the brand-name product

theglobeandmail.com

Health Canada to inspect three Grifols private plasma collection sites in Ontario

Locations in Toronto and Cambridge haven’t been inspected since opening last year

theglobeandmail.com

Health Canada urged to inspect three Grifols sites in Ontario amid safety concerns

Ontario NDP MPP says inspection system hasn’t adapted to rise in for-profit blood collection

theglobeandmail.com

Family of plasma donor who died calls for investigation over record inconsistencies

Rodiyat Alabede, 22, died after donating plasma at a Grifols collection centre in Winnipeg

theglobeandmail.com

Conservatives call for tighter Health Canada oversight of plasma centres after two deaths

Two donors have died in recent months after giving plasma at Grifols’ clinics in Winnipeg

theglobeandmail.com

Health Canada found multiple issues at Grifols’ Winnipeg clinic after death, inspector report shows

Document suggests federal health agency pointed out some of the same concerns repeatedly since 2022 without resolution

theglobeandmail.com

Canadians’ plasma is now a liquid asset. Is that ethical? I donated to learn more

For years, Canadians weren’t paid for a prized medical resource in their veins. Now, some are

theglobeandmail.com

Board chair of non-profit behind failed PrescribeIT defends CEO’s nearly $900,000 compensation

Pay was justified because it was on par with hospital executives, Peter Vaughan tells MPs

theglobeandmail.com

Health Canada approves generic Ozempic from Apotex, country’s largest drug maker

Apotex is first company to get approval that has domestic manufacturing presence

theglobeandmail.com

Head of non-profit paid nearly $900,000 a year despite failure of federal ‘axe the fax’ program

Failed program is under scrutiny for lack of uptake despite $300-million in federal funds spent

theglobeandmail.com

Health regulator authorizes Indian company to sell first generic Ozempic in Canada

Dr. Reddy’s Laboratories Ltd. has been authorized to sell the drug, Health Canada says

theglobeandmail.com